Table 2 Frequency of positivity of APLA in MS and controls
Target antigens | Exacerbation | Remission | Controls | |||
|---|---|---|---|---|---|---|
| Â | IGG | IGM | IGG | IGM | IGG | IGM |
β2-GP-I | 0/17 (0%) | 14/17 (82%) | 0/7 (0%) | 2/7 (28%) | 1/21 (4%) | 0/21 (0%) |
VIIa | 0/17 (0%) | 10/17 (59%) | 0/17 (0%) | 0/7 (0%) | 0/21 (0%) | 0/21 (0%) |
CL | 0/17 (0%) | 14/17 (82%) | 0/17 (0%) | 2/7 (28%) | 0/21 (0%) | 0/21 (0%) |
PC | 0/17 (0%) | 13/17 (76%) | 0/17 (0%) | 1/7 (14%) | 0/21 (0%) | 0/21 (0%) |
PS | 0/17 (0%) | 12/17 (71%) | 0/17 (0%) | 1/7 (14%) | 0/21 (0%) | 0/21 (0%) |
PE | 0/17 (0%) | 14/17 (82%) | 0/17 (0%) | 2/7 (28%) | 0/21 (0%) | 0/21 (0%) |
At least one | 0/17 (0%) | 15/17 (88%) | 0/17 (0%) | 4/7 (57%) | 1/21 (4%) | 0/21 (0%) |